The AGILE trial of ivosidenib plus azacitidine versus azacitidine alone: How many limitations is too many?

The AGILE trial compared ivosidenib and azacitidine versus azacitidine for IDH1-mutant acute myeloid leukemia (AML) in elderly patients who were ineligible to receive intensive chemotherapy. While the results of this trial appear encouraging, various concerns become evident from the study design and...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhatt, Anjali, Powell, Kerrington, Prasad, Vinay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9460510/
https://www.ncbi.nlm.nih.gov/pubmed/36063621
http://dx.doi.org/10.1016/j.tranon.2022.101523

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9460510/
https://www.ncbi.nlm.nih.gov/pubmed/36063621
http://dx.doi.org/10.1016/j.tranon.2022.101523

Ejemplares similares